The Immunomodulator Platform
The immunomodulator platform is Gliknik's most clinically advanced program with two compounds in clinical safety testing in patients. Immunomodulators increase CD4, CD8, and antibody immune responses against targeted cancer epitopes. These peptide drugs are currently in a standard dose-rising safety study in patients with very advanced Head and Neck Squamous Cell Carcinoma. Patients interested in learning more about the clinical trial should click here. A clinical trial in combination with autologous T cell therapy for patients with advanced myeloma has recently begun. Patients interested in learning more about the clinical trial should click here. The company expects to assess these drugs for utility in other cancers.